Beijing, China — In October 19-22, 2023, “The 30^th National Urology Academic Annual Conference (CUA2023)”, sponsored by Chinese Medical Association, Chinese Urology Association (CUA) and organized by Beijing Urology Association, was held at Beijing National Conference Center. MicroPort® MedBot® Group presented Toumai® Four-Arm Laparoscopic Surgical Robot (hereinafter referred to as the Toumai® Robot), Mona Lisa Robotic Prostate Puncture Positioning System (hereinafter referred to as the Mona Lisa Robot), Toumai® 5G Remote Console on the conference.

The launch event for Mona Lisa Robot was officially held following the opening of the main forum. Professor Jian Huang, Academician Xu Zhang and other experts were present and delivered their congratulatory speeches. Every expert was hoping that MicroPort® MedBot® would develop more state-of-art robots in the future, contributing to the development of the minimally invasive surgery in China. The “test drive” of the Toumai® Robot on site appealed to many visitors. Experts claimed that the excellent trial experience, as well as the accuracy and stability shown during the live surgery broadcast as assisted by Toumai® Robot, made us feel more confident in China-made surgical robots. They believed that China-made surgical robots could provide good treatment tools, treatment plans, and innovative platforms for urology and other surgeries.

In his congratulatory speech for the launch of Mona Lisa, Prof. Jian Huang stated that MicroPort® MedBot® Group, with its strong technical capabilities, was the first to obtain NMPA approval for the launch of laparoscopic surgical robots in the field of domestic robots. And it is worthy of celebration today with its official launch of this revolutionary product for prostate biopsy.

Academician Xu Zhang, in his speech, expressed his gratitude to MicroPort® MedBot® Group for its striving to present new products and technologies for the Chinese urology community, and to create a domestic brand deeply rooted in China. He was looking forward to the industry working together in the future to further promote the sustainable development and technological revolution of China-made medical robots.

Prostate biopsy is the gold standard for prostate cancer diagnosis and currently the only clinical testing method that can obtain confirmatory information on prostate cancer. As a revolutionary product for the prostate biopsy, Mona Lisa Robot becomes the first prostate puncture robot approved for use in urological surgery by National Medical Products Administration (NMPA). The puncture mode promoted by this robot is true shifting from manual puncture to intelligent robot puncture, thus it could serve as a powerful assistant for prostate cancer diagnosis and provide an integrated smart solution for precision diagnosis and treatment of prostate cancer, filling the blank of the domestic prostate puncture robot market.

At this conference, many experts shared their experiences by means of live streaming of minimally invasive urologic surgeries and related diagnostic and treatment technologies. Among them, Dr. Zheng Zhang, Chief Physician from the Urology Department of Peking University First Hospital presented a high-level and highly difficult case of robot-assisted partial nephrectomy in his teaching demo, all under the accurate and stable assistance of Toumai® Robot.

For the product debut on this CUA2023, the MicroPort® MedBot® booth attracted widespread attention from the attending peers. Lots of experts and physicians were coming here to get hands-on trial and gain in-depth understanding of the robot operations as well as the exploratory experience of the 5G telesurgery. Upon learning that Toumai® Robot had completed over 1,400 case of highly challenged combined surgeries, many experts said that they were surprised by the stable performance of the Toumai® Robot in assisted surgery. Some experts stated that surgical robots are state-of-art medical equipment increasingly applied in the field of minimally invasive surgery. The improvement in accuracy and safety of the robots has significantly changed the landscape of the minimally invasive surgery.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of the MicroPort® MedBot®, stated that domestic surgical robots should not only be smarter but also more inclusive in the future, making the robotic surgeries more affordable and spreading the services further down to the grassroot, which is also the motivation pushing MicroPort® MedBot® Group to keep on exploring 5G telesurgery in recent years. We have reasons to believe that in the foreseeable future, with the policy support from the Chinese government, and with the innovative development of domestic surgical robot technology and the popularized application of 5G telesurgery, the medical service quality in China will be effectively improved, the level of medical technologies will be more homogenized, and the uneven distribution of medical resources will be alleviated, thus allowing more patients to access high-level and high-quality medical services.